Rezdiffra
-
West Conshohocken’s Madrigal Pharmaceuticals Eyes $1B Expansion Deal
Madrigal Pharmaceuticals is making another major move in the rapidly growing liver disease treatment market, writes John George for The…
-
Conshohocken’s Madrigal Makes $4B Bet on the Future of Liver Disease Treatment
Conshohocken’s Madrigal Pharmaceuticals is making a major move that could reshape the future of liver disease treatment, writes John George…
-
Madrigal Pharmaceuticals Expands As Breakthrough Drug Fuels Growth
West Conshohocken’s Madrigal Pharmaceuticals is relocating its headquarters to accommodate rapid expansion, reports John George for The Philadelphia Business Journal.…
-
Conshohocken’s Madrigal Pharmaceuticals Reports Sales Through the Roof
Conshohocken’s Madrigal Pharmaceuticals, saw third-quarter sales soar for its NASH treatment, Rezdiffra, writes John George for the Philadelphia Business Journal.…
-
Madrigal Pharmaceuticals in Conshohocken Reports $14.6 Million in Sales from Groundbreaking NASH Drug Rezdiffra
Conshohocken-based Madrigal Pharmaceuticals generated $14.6 million in sales from Rezdiffra, its first and flagship product, during the second quarter of…
-
Conshohocken-based Madrigal Pharmaceuticals Launches Groundbreaking NASH Drug, Rezdiffra
In the less than two months since becoming the first drug developer to receive Food and Drug Administration clearance for…
-
Madrigal Pharmaceuticals First to Receive FDA Clearance for a NASH Treatment
Madrigal Pharmaceuticals has been given Food and Drug Administration market clearance for its experimental treatment for NASH, a fatty liver…
Founding Partners
Advertisement
Affiliate Partners
Community Partners
